TABLE 1.

MV-N binding on different cell types

Cell typea	N binding (MFI)b	Inhibition of N binding by anti-FcγRII ± IIIc	FcγRII expressiond	Predictive NR expressione
Epithelial cell lines
P1.4D6 (human postnatal cortical TEC)	++	No	−	+
3D1 (mouse cortical TEC)	+	No	−	+
HeLa (human carcinoma)	+	No	−	+
Fibroblast cell lines
MeWo (human melanoma)	+	No	−	+
NIH 3T3 (mouse)	++	No	−	+
Vero (monkey)	+	NDf	−	+
Monocytes/macrophages
Human	+	Partial	+	+
Mouse wt	+++	Partial	+	+
Mouse FcγRII/III−/−	++	No	−	+
DC
Human	+	Partial	+	+
Mouse wt	+++	Partial	+	+
Mouse FcγRII/III−/−	++	No	−	+
B cells
Primary resting mouse wt	+++	Partial	+	+
Primary resting mouse FcγRII/III−/−	++	No	−	+
T cells
Primary resting human	−	No	−	−
Primary resting mouse wt	−	No	−	−
Primary resting mouse FcγRII/III−/−	−	No	−	−
Human Jurkat	+	No	−	+
Human red blood cells	−	No	−	−

^aHuman and murine cells were isolated as described in Materials and Methods.

^bMV-N binding was performed as described in Fig. 2. However, MV-N binding to murine primary cells was assessed by double stainings. The results are expressed as described in Materials and Methods. MFI is indicated as follows: −, no binding; +, MFI between 10 and 50; ++, MFI between 50 and 100; +++, MFI >100.

^cInhibition of MV-N binding was determined after incubation of MV-N with blocking KB61 or 2.4G2 MAb against human or murine FcγRII/III, respectively. The results are expressed as the inhibition percentage of MFI and are indicated as no inhibition (no) or 30 to 70% inhibition (partial).

^dFcγRII/III expression was determined by using anti-human and anti-murine CD32/CD16 MAbs and is indicated as no expression (−) or FcγRII ± III expression (+).

^ePutative second receptor expression was deduced by analysis of MV-N bindings. All labelings were analyzed by flow cytometry, and data are expressed as the mean of three to five separate experiments (SD values are <15%).

^fND, not determined.